Health
Duchenne Drug Fails to Impress
Entrada Therapeutics’ next-generation Duchenne muscular dystrophy drug failed in an early-stage trial. The setback could impact the company’s stock and future research efforts.
Coverage timeline — 1 article
STAT News
A next-gen Duchenne therapy from Entrada Therapeutics fell short in an early study, as a number of companies race to make improved drugs.
2026-05-07 11:05 UTC